Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are oral diabetes medications that enhance the excretion of glucose by preventing the renal proximal tubules from reabsorbing glucose, which lowers glucose levels in plasma. Currently, studies have shown that SGLT2 inhibitors have beneficial impacts...

Descripción completa

Detalles Bibliográficos
Autores principales: Memon, Rahat A, Akbariromani, Hanieh, Vohra, Rimsha R, Kundi, Hayan, Saleem, Rao Faraz, Ghaffari, Muhammad abuzar, Haas, Donald, Khan, Areeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiac/Thoracic/Vascular Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404679/
https://www.ncbi.nlm.nih.gov/pubmed/36039257
http://dx.doi.org/10.7759/cureus.27277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404679/
https://www.ncbi.nlm.nih.gov/pubmed/36039257
http://dx.doi.org/10.7759/cureus.27277

Ejemplares similares